RHS: Reproductive Health Science




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: RHS: Reproductive Health Science
Released on: November 29, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Reproductive Health Science Ltd (RHS) was founded to develop advanced patented single cell genomic technologies.
  • Summary
  • Participants
  • Company
Reproductive Health Science Ltd (RHS) was founded to develop advanced patented single cell genomic technologies. These technologies originated from the Department of Obstetrics and Gynaecology at The University of Adelaide. RHS founding scientists wrote one of the first papers on the use of microarrays for Pre-implantation Genetic Screening in 2004. Fintan Walton, CEO of PharmaVentures interviews Dr Michelle Fraser, Managing Director and CEO, Reproductive Health Science
Dr Michelle Fraser, Managing Director and CEO, Reproductive Health Science
Reproductive Health Science Ltd (RHS) was founded to develop advanced patented single cell genomic technologies. These technologies originated from the Department of Obstetrics and Gynaecology at The University of Adelaide. RHS founding scientists wrote one of the first papers on the use of microarrays for Pre-implantation Genetic Screening in 2004 1 & 2. The research published in that paper formed the basis for patents and exclusive licences to RHS in Australia, the USA, Europe, China, New Zealand and Canada. Since its inception, RHS has maintained a consistent focus on improving health and research outcomes and has built an experienced team and significant know-how in the development of whole genome amplification and array Comparative Genomic Hybridisation tools. It is this expertise that has gone into RHS’s EmbryoCellect™ kit. RHS is located in the Bio Innovation SA Incubator in the heart of the Thebarton biotechnology precinct in Adelaide, South Australia. The company is listed on the Australian Stock Exchange (ASX).